VEGF/VEGFR Pathway Inhibitors as Anti-Angiogenic Agents: Present and Future

E-ISSN： 1873-5576|11|5|624-653

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.11, Iss.5, 2011-01, pp. : 624-653

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Development of Vascular Endothelial Growth Factor Receptor (VEGFR) Kinase Inhibitors as Anti-Angiogenic Agents in Cancer Therapy

Current Medicinal Chemistry, Vol. 11, Iss. 6, 2004-03 ,pp. : 731-745

Bentham Science Publishers

Access to resources Recommend Favorite

Anti-Angiogenic Therapy: Strategies to Develop Potent VEGFR-2 Tyrosine Kinase Inhibitors and Future Prospect

Current Medicinal Chemistry, Vol. 23, Iss. 10, 2016-03 ,pp. : 1000-1040

Bentham Science Publishers

Access to resources Recommend Favorite

The Molecular Basis of Class Side Effects Due to Treatment with Inhibitors of the VEGF/VEGFR Pathway

Current Clinical Pharmacology, Vol. 3, Iss. 2, 2008-05 ,pp. : 132-143

Bentham Science Publishers

Access to resources Recommend Favorite

Antiangiogenic Agents: an Update on Small Molecule VEGFR Inhibitors

Current Medicinal Chemistry, Vol. 14, Iss. 23, 2007-10 ,pp. : 2495-2516

Bentham Science Publishers

Access to resources Recommend Favorite

Kinase insert domain-containing receptor kinase inhibitors as anti-angiogenic agents

By Hartman George D Fraley Mark E Bilodeau Mark T

Expert Opinion on Investigational Drugs, Vol. 11, Iss. 6, 2002-06 ,pp. : 737-745

Informa Healthcare

Access to resources Recommend Favorite